Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04239040 · ClinicalTrials.gov registry record · Phase 1
GVAX Plus Checkpoint Blockade in Neuroblastoma
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT04239040 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 19 participants.
The verdict
NCT04239040, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
This research clinical trial is studying the creation and administration of GVAX, an irradiated GM-CSF secreting, autologous neuroblastoma cell vaccine (GVAX) in combination with nivolumab and ipilimumab as a possible treatment for neuroblastoma. The names of the study drugs involved in this study are: * GVAX Vaccine, an immunotherapy developed from surgically removed tumor tissue * Nivolumab * Ipilimumab
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
- PROCEDURE Tissue collection
- BIOLOGICAL GVAX vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-01-29 |
| Est. Completion | 2024-02-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04239040
The ClinicalTrials.gov registry entry for NCT04239040 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab is the first listed.
NCT04239040 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04239040 about?
NCT04239040 is a clinical study titled "GVAX Plus Checkpoint Blockade in Neuroblastoma". This research clinical trial is studying the creation and administration of GVAX, an irradiated GM-CSF secreting, autologous neuroblastoma cell vaccine (GVAX) in combination with nivolumab and ipilimumab as a possible treatment for neuroblastoma. The names of the study drugs involved in this study ...
What is the current status of trial NCT04239040?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2020-01-29. Estimated completion is 2024-02-29.
What interventions are being tested in trial NCT04239040?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG), Tissue collection (PROCEDURE), GVAX vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04239040?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.